Escherichia coli Inoculation Test in a Mouse Model of Mastitis: Protocol, Endpoints, and Application

The Escherichia coli inoculation test in a mouse model of mastitis is a well-established preclinical assay that reproduces acute bacterial mastitis by delivering a defined microbial load into the mammary glands of lactating mice. This model enables quantitative assessment of infection severity, inflammatory cascades, and therapeutic efficacy through integrated microbiological, histopathological, and immunological endpoints. This article outlines the standardized experimental protocol, sample types, measured parameters, analytical methods, and principal applications of the E. coli-induced murine mastitis model.

Technical Overview

Mastitis is the inflammation of the mammary gland, most frequently triggered by bacterial invasion through the teat canal. Escherichia coli is one of the leading etiological agents of acute coliform mastitis in dairy animals and an important pathogen in human lactational mastitis. Because it releases endotoxin (lipopolysaccharide, LPS) that potently activates the TLR4/NF-κB signaling axis, E. coli induces a rapid, severe inflammatory response characterized by neutrophil infiltration, edema, and damage to the blood-milk barrier.

The murine model of E. coli-induced mastitis is created by inoculating a standardized bacterial suspension directly into the mammary gland via the teat duct of lactating female mice, typically between days 7 and 14 of lactation. The model faithfully recapitulates the key pathological features of clinical coliform mastitis, including bacterial proliferation within glandular tissue, massive myeloperoxidase-positive neutrophil recruitment, elevated pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and disruption of tight junction proteins. The acute phase of the disease generally peaks between 24 and 48 hours post-inoculation, providing a compact and reproducible experimental window for efficacy and mechanistic studies.

Compared with large-animal models, the mouse model offers controlled infectious doses, genetic tractability, access to molecular tools, lower cost, and compatibility with rigorous randomization and blinded scoring designs. Studies are routinely conducted in accordance with institutional animal care and use committee (IACUC) approvals, the ARRIVE reporting guidelines, and applicable national laboratory animal welfare standards.

Testing Samples

Mammary Gland Tissue

The inoculated inguinal (fourth pair) mammary glands are harvested at defined endpoints, typically 24, 48, or 72 hours post-inoculation. One portion is fixed in 4% paraformaldehyde for histopathological examination, while the remainder is snap-frozen or homogenized in sterile cold saline or lysis buffer for bacterial enumeration, myeloperoxidase (MPO) activity assays, enzyme-linked immunosorbent assays (ELISA), and RNA or protein extraction.

Mammary Gland Homogenates and Lavage Fluid

Gland homogenates provide the primary matrix for colony-forming unit (CFU) quantification of the viable bacterial burden, cytokine protein measurement, and oxidative stress marker analysis. Ductal lavage fluid or expressed milk from infected glands may also be collected to assess somatic cell composition and local secretory immune mediators.

Whole Blood and Serum

Blood samples collected via submandibular venipuncture or terminal cardiac puncture are used for complete blood counts with differential leukocyte analysis, while separated serum supports measurement of systemic inflammatory markers such as serum amyloid A, pro-inflammatory cytokines, and endotoxin levels.

Testing Items

The E. coli inoculation test in the murine mastitis model typically encompasses the following categories of endpoints:

• Clinical observation scores: mammary gland swelling, erythema, skin temperature, body weight change, general activity, and pup nursing behavior
• Bacterial burden: viable E. coli counts expressed as CFU per gram of mammary tissue or per gland
• Histopathological evaluation: hematoxylin and eosin (H&E) stained sections scored in a blinded manner for neutrophil infiltration, alveolar and interstitial edema, epithelial damage, necrosis, and glandular architecture disruption
• Myeloperoxidase (MPO) activity: a quantitative surrogate marker of neutrophil accumulation in glandular tissue
• Inflammatory cytokines: protein and mRNA levels of TNF-α, IL-1β, IL-6, IL-10, and IL-8 homologs measured by ELISA and real-time quantitative PCR (RT-qPCR)
• Oxidative stress markers: superoxide dismutase (SOD), catalase (CAT), glutathione (GSH), glutathione peroxidase (GSH-Px), and malondialdehyde (MDA)
• Barrier integrity markers: expression of tight junction and adherens junction proteins, including ZO-1, occludin, claudins, and E-cadherin
• Hematological parameters: total white blood cell count and neutrophil-to-lymphocyte ratio
• Signaling pathway analysis: activation states of NF-κB p65, MAPK (p38, ERK, JNK), and NLRP3 inflammasome components by western blot or immunohistochemistry

Testing Methods

Experimental Design and Grouping

A typical study includes a sham-inoculated negative control group (sterile PBS vehicle), an infected model group, one or more treatment groups receiving the test compound, and a positive control group treated with a reference antibiotic. Animals are randomized to groups, sample collection time points are pre-specified, and outcome assessment is performed by analysts blinded to treatment allocation. Sample sizes are determined by power analysis based on expected effect sizes in CFU burden or cytokine levels.

Bacterial Culture and Inoculum Preparation

A well-characterized reference E. coli strain or a validated clinical mastitis isolate is cultured to logarithmic phase in appropriate broth, washed by centrifugation, and resuspended in sterile phosphate-buffered saline. The inoculum density is calibrated by optical density measurement and confirmed by back-titration through serial dilution and viable plate counting, ensuring that the delivered dose falls within the target range of approximately 10² to 10⁴ CFU per gland depending on strain virulence. All microbiological work is performed under biosafety level 2 conditions with documented sterility and purity controls.

Intramammary Inoculation Procedure

Lactating dams are anesthetized using an approved regimen such as inhaled isoflurane or injectable ketamine-xylazine. The teat orifice of the target inguinal gland is localized under magnification, and a fine needle or micro-syringe is inserted gently into the teat canal. A small inoculum volume, commonly 50 to 100 microliters, is infused slowly into the mammary ductal system, after which the pups are temporarily separated to prevent immediate suckling-induced clearance. Technicians experienced in the procedure perform inoculations to minimize ductal trauma and inter-animal variability.

Sample Collection and Processing

At scheduled endpoints, animals are euthanized by an approved method and mammary glands are rapidly dissected. Tissues for CFU counting are homogenized under cold, sterile conditions, serially diluted, plated on selective and non-selective agar, and incubated for colony enumeration. Tissues for histology are fixed, paraffin-embedded, sectioned, and stained with H&E for blinded pathological scoring. Aliquots for ELISA, MPO assays, RT-qPCR, western blotting, and oxidative stress analysis are processed using validated, kit-based or instrument-based methods with appropriate internal standards and replicate wells.

Quality Control and Animal Welfare

Each experimental run includes inoculum back-titration, negative and positive assay controls, and calibration verification for quantitative platforms. Studies are executed in GLP-aligned or ISO-standardized laboratory environments where applicable. Humane endpoints, adequate analgesia and anesthesia, minimal animal numbers consistent with the Three Rs principles, and continuous welfare monitoring are mandatory elements of the protocol.

Applications

The E. coli-induced murine mastitis model is extensively applied across pharmaceutical, veterinary, nutraceutical, and academic research contexts, including:

• Preclinical efficacy evaluation of antibiotic candidates, including dose-response and resistance-relevant pharmacodynamic profiling
• Screening of anti-inflammatory agents, such as NF-κB and NLRP3 pathway inhibitors, for their ability to attenuate cytokine storms and tissue damage
• Assessment of natural products, plant extracts, polysaccharides, peptides, nanoparticles, and probiotics with antimicrobial or immunomodulatory properties
• Evaluation of bacteriophage therapeutics and alternative antimicrobial strategies intended to reduce antibiotic use in dairy production
• Vaccine and immunomodulator testing, including measurement of bacterial clearance acceleration and enhanced innate immune priming
• Mechanistic studies of host-pathogen interactions, virulence factor contributions, tight junction regulation, and mammary gland innate immunity
• Biomarker discovery and target validation supporting translational research into both bovine and human mastitis

FAQ

Which mouse strain and physiological stage are used for this model?

Commonly used strains include BALB/c, C57BL/6, and ICR (CD-1) female mice during established lactation, typically 7 to 14 days postpartum, when the mammary ductal system is fully developed and accessible for teat canal inoculation.

How is the model confirmed as successfully established?

Successful model establishment is verified by a combination of elevated viable bacterial counts in gland tissue, significant histopathological lesions with marked neutrophil infiltration, increased MPO activity, and significantly upregulated TNF-α, IL-1β, and IL-6 levels relative to sham controls.

What is the typical experimental duration?

The acute inflammatory phase is generally examined at 24 to 48 hours post-inoculation, with some protocols extending observation to 72 or 96 hours to capture bacterial clearance kinetics, tissue repair, or delayed treatment effects.

How relevant is the mouse model to clinical bovine or human mastitis?

The model reproduces the core immunopathology of acute coliform mastitis, including LPS-driven TLR4 signaling, neutrophil-dominated inflammation, and blood-milk barrier disruption, making it a widely accepted preclinical surrogate, while confirmatory studies in target species remain necessary for final translation.

Can this model be used to support regulatory submissions?

Yes. When performed in GLP-compliant or accredited third-party laboratories with documented quality systems, validated analytical methods, and complete raw data traceability, results from this model can support preclinical efficacy packages for veterinary pharmaceutical, biological, and feed-additive product development.

What welfare safeguards are in place?

All procedures require prior approval by an institutional animal care and use committee, adherence to national animal welfare regulations, defined humane endpoints, appropriate anesthesia and analgesia, and daily monitoring by trained veterinary staff throughout the study period.